• Tags: FDA approval
FDA approves extended Vabysmo label for macular edema following RVO
Products

FDA approves extended Vabysmo label for macular edema following RVO

Updated labeling enables IVT treatment beyond 6 months, intended to enable more flexible and tailored treatment plans.
FDA clears Bausch + Lomb's Bi-Blade+ vitrectomy cutter and fluidics technology
Products

FDA clears Bausch + Lomb's Bi-Blade+ vitrectomy cutter and fluidics technology

Dual-port vitrectomy cutter increases cutting speed from 15K to 25K per minute, while Adaptive Fluidics update expands capabilities of the Stellaris Elite system
FDA clears the OCULUS Pentacam Cornea OCT
Products

FDA clears the OCULUS Pentacam Cornea OCT

Diagnostic device combines OCT and Schleimpflug imaging to provide advanced cornea visualization via a single, 1-second measurement process.
FDA approves expanded EYLEA HD dosing intervals
Products

FDA approves expanded EYLEA HD dosing intervals

VEGF inhibitor cleared for every 20 weeks among wet AMD and DME patients; clearance based on 96-week data from the PHOTON and PULSAR pivotal trials.
FDA approves J&J's TECNIS PureSee IOL for cataract patients
Products

FDA approves J&J's TECNIS PureSee IOL for cataract patients

Approval is the first extended-depth-of-focus lens with no warning on loss of contrast sensitivity; availability to follow later this year.
FDA tentatively approves Gland Pharma's brimonidine tartrate 0.025% generic
Products

FDA tentatively approves Gland Pharma's brimonidine tartrate 0.025% generic

Final approval and U.S. market launch are still pending for the generic version of Bausch + Lomb’s over-the-counter LUMIFY redness reliever drops.
FDA approves expanded age indication for STAAR's EVO/EVO+ Visian ICLs
Products

FDA approves expanded age indication for STAAR's EVO/EVO+ Visian ICLs

U.S. age indication now includes patients aged 21 to 60 years old, making nearly 8 million refractive patients eligible for implantable collamer lens implantation.
FDA approves DifGen's fluorometholone 0.1% complex generic for ocular inflammation
Products

FDA approves DifGen's fluorometholone 0.1% complex generic for ocular inflammation

Prescription-based corticosteroid suspension is the second generic of AbbVie’s FML 0.1% to receive regulatory approval.
FDA approves Tenpoint's YUVEZZI as first dual-agent presbyopia drop
Products

FDA approves Tenpoint's YUVEZZI as first dual-agent presbyopia drop

First and only combination drop of carbachol and brimonidine tartrate achieves miosis within 30 minutes and lasts up to 10 hours following once-daily dosing.
FDA approves Glaukos' iDose TR for repeat treatment labeling
Products

FDA approves Glaukos' iDose TR for repeat treatment labeling

Travoprost intracameral implant can now be re-administered using a repeat treatment protocol—enabling greater flexibility in glaucoma patient management.
FDA approves Alembic's difluprednate 0.05% generic
Products

FDA approves Alembic's difluprednate 0.05% generic

Generic version of Sandoz’s Durezol is indicated for postop pain and inflammation as well as endogenous anterior uveitis.
FDA clears Rayner's Sophi phacemulsification system
Products

FDA clears Rayner's Sophi phacemulsification system

First battery-powered, wireless phaco system features triple pump fluidics for more control of anterior chamber stability during cataract surgery.
FDA approves Gland Pharma's OTC Extra Strength Pataday generic
Products

FDA approves Gland Pharma's OTC Extra Strength Pataday generic

Olopatadine HCl ophthalmic solution 0.7% is indicated to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander for 24 hours.
FDA clears first EDOF contact lens for presbyopia
Products

FDA clears first EDOF contact lens for presbyopia

U.S. approval is first for a daily disposable, extended-depth-of-field lens requiring no patient cognitive adaptation period for presbyopia correction.
FDA approves Formycon and Bioeq's Lucentis biosimilar
Products

FDA approves Formycon and Bioeq's Lucentis biosimilar

Nufymco (ranibizumab-leyk) marks the companies’ second ranibizumab biosimilar cleared in the U.S. to treat five retinal indications.
FDA approves Alembic Pharma's loteprednol etabonate and tobramycin ophthalmic suspension
Products

FDA approves Alembic Pharma's loteprednol etabonate and tobramycin ophthalmic suspension

Generic of Bausch + Lomb’s ZYLET for steroid-responsive inflammatory ocular conditions qualifies for 6 months of market exclusivity once commercially launched.
Amneal receives FDA approval for Restasis generic
Products

Amneal receives FDA approval for Restasis generic

Generic version of Allergan’s cyclosporine ophthalmic emulsion 0.05% eye drop for dry eye is the second to receive U.S. regulatory clearance.
FDA approves new EYLEA HD indication, expanded dosing intervals
Products

FDA approves new EYLEA HD indication, expanded dosing intervals

Intravitreally-administered 2 mg aflibercept therapeutic is now cleared for macular edema following retinal vein occlusion.
FDA clears Topcon's OMNIA auto kerato-refracto tonometer
Products

FDA clears Topcon's OMNIA auto kerato-refracto tonometer

Now commercially available, the fully automated ophthalmic device offers refraction, keratometry, tonometry, and pachymetry.
FDA approves Glaukos' Epioxa corneal CXL therapy
Products

FDA approves Glaukos' Epioxa corneal CXL therapy

Second-generation CXL therapy is now the first FDA-approved topical drug therapy that does not require removal of the corneal epithelium.